Harvard Bioscience Announces Reverse Stock Split
Affected assets and topics
Why it matters
Harvard Bioscience announced a 1-for-10 reverse stock split, effective March 16, 2026, which may increase the stock's value by reducing the number of outstanding shares, but may also make it less accessible to individual investors.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 80% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 54660
- Timeframe
- 6h
Prediction lifecycle
-
Llama 3.1 8B Instant (Groq) NASDAQ Bullish 80%Generated 6h Excluded
Expired: not evaluated within 7 days of its 6h timeframe elapsing
Logged at publication, scored automatically once the window closes — never edited.
Original source
Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value $0.01 per share. The Reverse Split was approved
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on March 7, 2026. Analysis and insights provided by AnalystMarkets AI.